Kornimate/medical-research-clean huggingface dataset:
evaluation of a new self-assessed, home-based symptom score test in cat allergic patients

Conditions: Cat Allergy

Summary: the purpose of this study is to better standardize the symptom recording of cat allergic persons under real-life conditions. a new self-assessed, home-based symptom score will be tested.

in order to bring research on cat dander allergy a step further we aim to investigate cat dander allergy symptoms and record them in a natural environment, respectively, i.e. at the participant's home. for this purpose we aim to test a new self-assessed, homebased symptom score (called hyposcore). the participants will perform 8 provocation tests. every provocation test consists of petting the cat until the participants become symptomatic. the participants have to pet the cat everytime in the same manner. directly before and after the provocation test the symptoms will be recorded in the ecrf by using an ipad mini.

Eligibility criteria:
inclusion criteria: * participant understands the nature, meaning and scope of the study. * signed informed consent after being informed. * male and female patients 18 years to 65 years of age. * positive screening prick test (mean wheal diameter ≥ 3 mm) when tested with already standardized cat allergen extract. * positive screening prick test (wheal diameter ≥ 3mm) to histamine dihydrochloride 10mg/ml. * positive scratch test when tested with cat dander sample of participant's cat. * baseline symptoms with a severity of at least "1" in minimal 2 various symptoms. * owner of a cat that lives in the same household. exclusion criteria: * impaired in understanding the nature, meaning and scope of the study or incapable of giving written informed consent * participation in another study with investigational drug within the 30 days preceding and during the present study * women who are pregnant or breast feeding * intention to become pregnant during the course of the study * positive skin reaction in the prick test to negative control * history of anaphylactic reaction to pet allergens * severe diseases influencing the results of the present study by discretion of the investigator * immunotherapy with fel d 1 / cat allergen preparation during the past two years * skin lesions and excessive hair-growth in the skin test areas * treatment with prohibited concomitant medications with the exception of medications with local effects which will not influence the results of the skin tests and the results of the other tests (testing period). * the patient should not suffer from other respiratory allergies during this study

Keywords: cat allergy symptom score
t-prf versus t-prf and low-level laser stimulation on bone healing at posterior mandibular fractures

Conditions: Posterior Mandibular Fractures

Summary: different types of grafting substances have been used in the recent decade to accelerate bone healing at large bony facial defects. prf was one of the gold standard materials to be used until it was replaced by its successor t-prf due to the prf hazards of preparation. however, t-prf- still can't stand alone in full bone enhancement procedure. therefore, the combination with another bone bio-modulation technique, like low-level laser therapy, is a must to approach the full advantage of bone healing. aim: to compare between the effect of using t-prf versus t-prf with low level laser stimulation on bone healing at posterior mandibular fractures


Eligibility criteria:
inclusion criteria: * patients suffering from posterior mandibular fracture exclusion criteria: * patients with an untreated old mandibular fracture. * patient with hematological diseases (thrombocytopenia, hemorrhagic disease, and diabetes). * comminuted fracture with bone loss. * there is an infection at the fracture line.
effects of statins on lower extremity arterial function assessed by magnetic resonance imaging

Conditions: Diabetes

Summary: cholesterol-lowering drugs called statins improve the functioning of the endothelium, and help prevent heart disease. the investigators are testing whether statins improve endothelial function more in the arteries that have worse endothelium to begin with. one of the functions of the endothelium is to help control how blood vessels dilate (expand) or contract (narrow) in different situations. this affects how blood flows through those vessels. magnetic resonance imaging (mri) can be used to evaluate endothelial function in the arms and legs noninvasively.

correct

Eligibility criteria:
inclusion criteria: * age 40-90 * male or female * type 2 diabetes exclusion criteria: * known pregnancy or nursing. * females of child bearing potential must have been surgically sterilized or be post menopausal. * smoking * known vascular disease * inability to complete mri scan * symptoms of claudication * use of a nitrate medicine * use of any cholesterol-lowering agent * ldl \< 70 * acute illness * liver disease * contraindication to getting an mri scan (i.e. electronic implant, shrapnel, cerebral aneurysm clip, welding history).
hula, a physical activity intervention for female-cancer survivors

Conditions: Physical Activity; Breast Cancer; Cervical Cancer; Ovarian Cancer; Endometrial Cancer

Summary: a six-month interventional program to determine the biological and psychosocial effects of hula as a form of physical activity for female breast, cervical, endometrial or ovarian cancer survivors living on oahu.


Eligibility criteria:
inclusion criteria: * lives on oahu * diagnosed with primary breast,cervical, endometrial or ovarian cancer (stage i-iii) * completed initial regional and systemic treatment for breast cancer 2 months ago * physically capable of doing the hula-based physical activity * receives approval by attending physician to participate in trial exclusion criteria: * currently undergoing chemotherapy or radiation therapy

Keywords: hula breast cancer female hawaii physical activity cervical cancer ovarian cancer endometrial cancer
behavior and driving safety study

Conditions: Alcoholic Intoxication

Summary: the purpose of this study is to determine whether brief motivational interviews reduce the likelihood of driving under the influence of alcohol (dui).

despite extensive legislative, law enforcement, and public awareness efforts, driving under the influence of alcohol (dui) remains a major cause of mortality and loss of years of productive life. a brief motivational interview (bi) is a non-confrontational, patient-centered discussion during which the individual's motivation and confidence to change health-related behaviors are explored. previous studies of bis in health care settings suggest that bis administered after hospitalization for alcohol-related injury reduce the likelihood of repeat injury hospitalization and arrest for dui.

Eligibility criteria:
inclusion criteria: * second or greater arrest for driving under the influence of alcohol * arrest involved operation of a motor vehicle * at least 18 years of age * english-speaking exclusion criteria: * arrest involved injury to another person * previous participation in this study

Keywords: automobile driving driving under the influence interview, psychological brief intervention brief motivational interview
stereotactic body radiotherapy for stage i-iii prostate cancer

Conditions: Prostate Cancer; Prostatic Cancer; Prostate Neoplasms; Prostatic Neoplasms; Cancer of the Prostate

Summary: the purpose of this study is to find out the effects (good and bad) of highly focused radiation on you and your prostate cancer. the purpose of this evaluation is to see if this treatment causes fewer side effects that other standard treatment approaches, and to evaluate the effect of this treatment on your prostate tumor and your quality of life over time.


Eligibility criteria:
inclusion criteria: * histologically proven prostate adenocarcinoma * clinical stage t1a-t3, n0-nx, m0-mx * patients belonging in one of the following risk groups: (1) low risk: cs t1a-t2a, gleason 2-6, psa\<10, nx-0, mx-0; (2) intermediate risk: cs t2b, gleason ≤7, psa\<20, nx-0, mx-0, or cs t1a-t2b, gleason 2-6, psa≥10 \& \<20, nx-0, mx-0, or cs t1a-t2b, gleason 7, psa≤20, nx-0, mx-0; or (3) high risk: cs t2c-t3, any gleason, any psa, or cs t1-3, gleason ≥8 and/or psa≥20 * karnofsky performance status 70-100 * hormone therapy: includes lhrh agonists (e.g. leuprolide, goserelin, triptorelin), antagonists (e.g. degarelix), peripheral blockers (e.g. flutamide, bicalutamide, nilutamide), estrogens (e.g. des) and bilateral orchiectomy * low and intermediate risk groups: no hormone ablation for two months prior to enrollment, or during treatment * high risk group: three hormone therapy regimens are allowed * 5-alpha reductase inhibitors (e.g., finasteride or dutasteride) are allowed exclusion criteria: * prior prostatectomy or cryotherapy of the prostate * prior high-dose radiotherapy to the prostate or lower pelvis * implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion

Keywords: radiation stereotactic radiosurgery radiotherapy prostate tumor prostate surgery cyberknife
effects of a female hormone balance supplement on premenstrual syndrome symptoms

Conditions: Premenstrual Syndrome

Summary: this virtual single-group study evaluates the effects of the femmebalance supplement on symptoms of premenstrual syndrome (pms) over four menstrual cycles. the study involves daily intake of the supplement, regular questionnaires, and skin photo submissions for dermatological grading.


Eligibility criteria:
inclusion criteria: * female, aged 18-40. * self-reported symptoms of pms for at least three consecutive months, including but not limited to pelvic pain, mood swings, acne, hair loss, fluid retention, breast pain/tenderness, irritability, and episodes of crying or sadness. * generally healthy and not living with any uncontrolled chronic disease. * has a regular menstrual cycle between 21 and 35 days in length. * willing to maintain the same diet, sleep schedule, and activity level for the duration of the study (at least 16 weeks). * own a smartphone with a camera. * must reside in the united states. exclusion criteria: * any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders. * anyone with known severe allergic reactions that require the use of an epi-pen or any allergies to any of the product ingredients. * women who are pregnant, breastfeeding, or trying to conceive. * anyone who is unwilling or unable to follow the study protocol. * anyone previously diagnosed with premenstrual dysphoric disorder (pmdd), endometriosis, or any cancer of the reproductive system. * anyone who is peri- or post-menopausal. * anyone who is currently on hormonal birth control or who has been on hormonal birth control in the last three months. * anyone who is taking any products, medication, or supplements that target the symptoms of pms. * anyone who has undergone any surgeries or invasive treatments in the last six months or who is planning on undergoing any in the study duration. * anyone who has had any major illness in the last three months. * anyone who is currently undergoing, or who plans to undergo in the study period, any procedures relating to reproductive health and/or the menstrual cycle, e.g., a hysterectomy, ovary removal, or similar procedure. * anyone who suffers from amenorrhoea or irregular periods (\ 35 days apart on average). * anyone who is currently participating in or who plans to participate in another trial during the study period. * anyone with a history of substance abuse. * anyone who smokes or who has been a smoker in the past three months.

Keywords: pms hormonal supplement female hormone balance
allied health in rheumatology triage project

Conditions: Inflammatory Arthritis

Summary: there is accumulating evidence that early treatment leads to better outcomes for patients with inflammatory arthritis (ia). triage, which is the process of identifying the urgency of a patient's disease state efficiently and correctly, may facilitate early referral to a rheumatologist. several studies have suggested that placing allied health professionals (occupational therapists, physical therapists, nurses, etc.) in a triage roll may reduce wait time for patients with suspected ia. the goal of this investigation will be to demonstrate the system-level impact of an arthritis society extended role occupational therapist (ot) or physical therapist (pt) working in a triage role in improving access to rheumatologists for people with ia. in this study two groups will be observed: intervention and "usual care" as determined by historical chart review. wait times will be compared between both groups.


Eligibility criteria:
inclusion criteria: * new referrals from a gp * adults with possible ia (determined by rheumatologist through paper triage) exclusion criteria: * currently on a disease-modifying antirheumatic drug (dmard) * previously seen by a rheumatologist. * fm, non-ia oa; soft tissue rheumatism; mechanical lbp

Keywords: psoriatic arthritis ankylosing spondylitis rheumatoid arthritis seronegative
stress hormones and iuds

Conditions: Contraception; Mood Change

Summary: determine what kind of side effects women experience in the first year after they start using an intrauterine device.

the purpose of this study is to find out if there is a difference in levels of stress hormones in women who use copper or hormonal intrauterine devices (iuds). this study will provide more information on the potential effect of levonorgestrel intrauterine system (lng-ius) use on an individual's stress response. ultimately, this study hopes to provide data to better counsel women on potential mood effects of the lng-ius. from a research and clinical management perspective, hair cortisol may provide a tool to evaluate women at risk for discontinuation of hormonal contraception due to concern of mood symptoms.

Eligibility criteria:
inclusion criteria: * generally healthy * age 18-39 years * regular menstrual cycles * getting an iud for the purpose of contraception exclusion criteria: * history of mood disorders * bmi less than 18.5 or greater than 35 * chronic medical conditions * recently pregnant or lactating

Keywords: intrauterine device (iud) depression stress hormones mood changes
oral pilocarpine in the treatment of the dry eye of patients with sjogrens syndrome

Conditions: Dry Eye

Summary: the purpose of this study was to access the possible beneficial effects of oral use of pilocarpine in relieving signs and symptoms of patients with sjogren's syndrome

after being informed about the study, its potential risks and having signed the informed consent form, this placebo-controlled, crossover study involved patients with sjögren's syndrome to use oral pilocarpine or placebo for ten weeks and after two weeks of medication withdrawal, to invert the treatment for the same period of time. the assessments applied were the ocular surface disease index, nei-vfq-25 questionnaire, non-invasive break-up time, traditional break-up time, evaluation of the cornea and ocular surface with fluorescein and rose bengal dyes, schirmer test, and tear ferning test. side effects observed during the treatment period were also assessed.

Eligibility criteria:
inclusion criteria: * patients with sjögren's syndrome, both in primary and secondary forms, whose diagnoses were established according to the criteria defined by the - american-european consensus for the diagnosis of sjögren's syndrome. * patients with the secondary form of the syndrome, collagen disease considered controlled by a rheumatologist, before the start of the trial and stable until the end of the study. * systemic therapy instituted up to two months before the beginning of the protocol. * literate patients. * signature of the informed consent form exclusion criteria: * eye or eyelid surface disease not attributed to sjogren's syndrome. * temporary or permanent occlusion of tear points. * use of contact lenses. * use of systemic medication that is known to influence tear flow. * need to modify the systemic treatment of the underlying disease during the trial. * pregnancy or breastfeeding. * known hypersensitivity reaction to pilocarpine hydrochloride. * severe cardio-pulmonary disease.

Keywords: dry eye sjogren pilocarpine hydrochloride
intermittent oro-esophageal tube feeding in late dysphagia for nasopharyngeal carcinoma

Conditions: Dysphagia

Summary: this is a prospective multicenter study with patients with delayed dysphagia after radiotherapy. patients enrolled are randomly divided equally into the observation group and the control group. all patients receive conventional care, and the observation group received intermittent oro-esophageal tube feeding while the control group received nasogastric tube feeding for enteral nutrition support. baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life after treatment as well as adverse events are compared.

palliation to delayed dysphagia after radiotherapy for nasopharyngeal carcinoma continues to be a challenge. this is a prospective multicenter study with patients with delayed dysphagia after radiotherapy. patients enrolled are randomly divided equally into the observation group and the control group. all patients receive conventional care, and the observation group received intermittent oro-esophageal tube feeding while the control group received nasogastric tube feeding for enteral nutrition support. baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life after treatment as well as adverse events are compared.

Eligibility criteria:
inclusion criteria: * age between 18 and 65 years. * with the history of nasopharyngeal carcinoma and radiation therapy. * with dysphagia occurred at least three years after radiotherapy (confirmed by videofluoroscopic swallowing study), in need of and feasible for enteral nutrition support. * conscious and with stable vital signs; * willing to participate and sign the written informed consent form either personally or by a family member. exclusion criteria: * presence of other diseases that might cause dysphagia. * with distant metastasis of tumors, or complicated with severe systemic disorders or malignancies. * concurrent participation in other treatments that could interfere with the trial. * inability to cooperate with treatment due to aphasia, mental health issues, etc. * received tube feeding for enteral nutrition support within the past three years.
ipi-926 extension protocol for continuation of treatment with ipi-926

Conditions: Basal Cell Carcinoma; Chondrosarcoma

Summary: a treatment protocol that enables patients to have continued access to ipi-926.

the extension protocol is a continuation of treatment with ipi-926, as administered to each individual patient during participation in their original ipi-926 protocol. patients who are completing their participation in the original ipi-926 protocol in which they enrolled, as defined in the original protocol, and, have stable disease or confirmed complete or partial response as defined by the original protocol may continue to receive treatment with ipi-926 in the extension protocol.

Eligibility criteria:
inclusion criteria: 1. voluntarily sign the informed consent form 2. currently receiving ipi-926 while participating in an infinity-sponsored ipi-926 study. note: for blinded studies, patient's treatment assignment must be unblinded according to the instructions in the original protocol to confirm they are receiving ipi-926. 3. eastern cooperative oncology group (ecog) performance status: 0 or 1. 4. documented response or stable disease, as defined in the original protocol, at the time of entry to the extension study. 5. willingness and ability to continue ipi-926 dispensation and follow-up procedures at the current investigational site. 6. willingness and ability to comply with scheduled visits, treatment plans, and laboratory tests and other study procedures. 7. women of child-bearing potential (wcbp), defined as a sexually mature woman who has not undergone a hysterectomy or tubal ligation or who has not been naturally postmenopausal for at least 24 consecutive months, must have a negative serum or urine pregnancy test prior to treatment. all wcbp, all sexually active male patients, and all partners of patients must agree to use adequate methods of birth control throughout the study. exclusion criteria: 1. discontinued ipi-926 or withdrew informed consent to participate in original infinity-sponsored ipi-926 study. 2. require addition of or change to a new concomitant therapy to adequately treat the malignancy under study.
multi-site, longitudinal trial evaluating the efficacy, mechanisms, and moderators of service dogs for military veterans with ptsd

Conditions: Stress Disorders, Post-Traumatic; Combat Stress Disorders; Animal-Human Bonding

Summary: posttraumatic stress disorder (ptsd) among military veterans is a critical public health concern. veteran suicide rates exceed those of the general population, with the disorder creating a mental health challenge that is costly and debilitating. the majority of veterans with ptsd also have comorbid mental health diagnoses, such as generalized anxiety disorder, substance abuse disorder, and major depression. the treatment of veteran ptsd and comorbid disorders represents an important therapeutic and rehabilitation problem. the disorder is complex and difficult to treat, with high treatment dropout and nonresponse rates spurring some veterans to seek complementary integrative health strategies. one promising complementary strategy is the provision of a trained service dog. initial evidence across multiple research groups highlights service dogs as a promising complement to evidence-based practices that can offer short-term improvements. however, the long-term effectiveness, mechanisms of action, and moderators of efficacy remain largely unknown. thus, the overarching objective of this proposal is to understand how, why, and for whom ptsd service dogs are most effective. to address this objective, the present project will assess the longitudinal efficacy and dose-response curve of service dogs for veteran ptsd symptomology and psychosocial functioning. the research design will consist of a two-arm, randomized clinical trial (rct) with longitudinal assessments over a period of 15 months. results are expected to elucidate the clinical impact of service dogs for military veterans with ptsd, as well as the biobehavioral mechanisms of action and characteristics that moderate efficacy. these outcomes will support the long-term goal of accelerating complementary and integrative health interventions, through optimized and evidence-based service dog interventions. as such, this project will further advance the scientific understanding of human-animal interactions for psychosocial health.


Eligibility criteria:
inclusion criteria: * applied for and approved to receive a psychiatric service dog from canine companions, k9s for warriors, or america's vetdogs * first service dog (not a successor service dog) * military service * honorable discharge or current honorable service * diagnosis of ptsd * no conviction of any crimes against animals